Evaluation of Cerebral Oxygenation Results in Premature Infant

April 11, 2023 updated by: Fatma Taş Arslan, Selcuk University

Evaluation of Cerebral Oxygenation Results in Premature Infants: Kangaroo Care and Facilitated Tucking Example

The general purpose of this project is; Evaluation of cerebral oxygenation results in premature infants.

These results will be evaluated in two different applications. The first practice and the first sub-aim of the study is to determine the effect of kangaroo care on cerebral oxygenation (rSO2) in premature infants.

The second application and purpose is to determine the effect of giving the infant the facilitated tucking position by hand and the nesting bed on the cerebral oxygenation (rSO2) of the infant during the heel blood collection process.

The study will be conducted between December 2020 and December 2021 at Level III NICU at the Medical Faculty Hospital in Konya.

Study Overview

Detailed Description

The general purpose of this project is; To determine the effect of kangaroo care and facilitated tucking position on cerebral oxygenation (rSO2) in premature infants.

In this context, the study has two sub-objectives. First sub purpose; to determine the effect of kangaroo care application given to premature inafants hospitalized in the NICU with the mother on cerebral oxygenation (rSO2), physiological parameters (heart rate, peripheral oxygen saturation (SpO2) and respiratory rate) and comfort / comfort levels.

This study was designed as a single blind, parallel group, pre-test and post-test randomized controlled trial.

First sub purpose; total sample size was determined as 40 preterm babies (20 in each group). Block randomization was used in this study. During the data collection phase, the purpose of the study will be explained to the parents of preterm infants by the researcher, and written consent will be obtained from the parents who agree to participate in the study through the "Informed Consent Form". Introductory Information Form, Physiological Parameter and rSO2 Follow-up Chart and Neonatal Comfort Scale created by the researcher will be used.

Second sub purpose; to determine the effect of facilitated tucking position on the infant's cerebral oxygenation (rSO2), physiological parameters (heart peak beat, SpO2 and respiratory rate), pain and comfort / comfort levels during the heel stick procedure.

This study was designed as a single blind, parallel group, two intervention groups in pre-test and post-test order, and a randomized controlled control group.

Second sub purpose; the total sample size was determined as 66 (22 in each group). Block randomization was used in this study. During the data collection phase, the purpose of the study will be explained to the parents of preterm infants by the researcher, and written consent will be obtained from the parents who agree to participate in the study through the "Informed Consent Form". The Introductory Information Form, Physiological Parameters and rSO2 Tracking Chart, PIPP-R and Neonatal Comfort Scale created by the researcher will be used.

Study Type

Interventional

Enrollment (Actual)

106

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Selcuklu
      • Konya, Selcuklu, Turkey, 42060
        • Selcuk University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 8 months (Child)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Adjusted gestational age of 28-36(+6) weeks at time of registration

Exclusion Criteria:

  • Mechanical ventilation,
  • Major congenital abnormalities,
  • Surgical or severe medical morbidity (bronchopulmonary dysplasia, NEC, sepsis, or intraventricular bleeding)
  • The mother is under 18 years of age
  • The mother is not willing to do kangaroo care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Kangaroo care

No Intervention: Standard care The control group will be followed by infants using nesting in the incubator. It will be followed for 60 minutes without any action or application.

Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.

Experimental: Kangaroo care The mother kangaroo will care for at least 60 minutes.
Experimental: Facilitated tucking position

No Intervention: Standard care In the Control Group, the heel stick procedure will be performed in the infants own bed as in the clinical routine.

Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.

Experimental 2: Facilitated Tucking Position, with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure.

Experimental 1: Manual Facilitated Tucking Position, infants will be given a manual facilitated tucking position during the heel stick procedure.

Experimental 2: Facilitated Tucking Position with the Nesting Bed (Tortoise Neo Bed), the facilitated tucking position will be given by the clinic nurse with the nesting bed during the heel stick collection procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The first sub-purpose Outcome: rSO2 level
Time Frame: Change from baseline and 70 min
Defines the change of rSO2 level. The NIRS monitor (COVIDEN Operations Manual INVOS® System, Model 5100C) was used to monitor rSO2 levels. The normal range of the rSO2 measured by the device was between 55% and 85%.
Change from baseline and 70 min
The first sub-purpose Outcome: physiological parameters of the premature infant- heart rate (min).
Time Frame: Change from baseline and 70 min
Defines the change of heart rate (min) level.Philips IntelliVue MP40 device was used to monitor respiratory rate. Philips IntelliVue MP40 device was used to monitor heart rate (min).
Change from baseline and 70 min
The first sub-purpose Outcome: physiological parameters of the premature infant- SpO2 level
Time Frame: Change from baseline and 70 min
Defines the change of SpO2 level.
Change from baseline and 70 min
The first sub-purpose Outcome: Neonates COMFORTneo scale
Time Frame: Change from baseline and 70 min
The COMFORTneo scale is a Likert-type scale consisting of seven parameters: alertness, calmness/agitation, respiratory response, crying, body movements, facial tension, and muscle tonus. The items are rated between 0 and 10, and the score that can be obtained from the scale ranges between 6 and 30. A score of 4-6 indicates moderate pain and distress and that of 7-10 indicates severe pain and distress.
Change from baseline and 70 min
The first sub-purpose Outcome: physiological parameters of the premature infant-respiratory rate (min)
Time Frame: Change from baseline and 70 min
Defines the change of respiratory rate (min) level.
Change from baseline and 70 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The second sub-purpose Outcome: Premature Infant Pain Profile Scale-Revised (PIPP-R)
Time Frame: Change from baseline and 70 min
The PIPP-R scale includes 3 behavioral (frowning, squeezing eyes, nasolobial-groove), 2 physiological (heart rate and oxygen saturation) and 2 contextual (behavioral state and gestational age) items used in the assessment of pain in newborns. The items of the scale are scored as 3, 2, 1, 0 ((0-6 points that the pain is mild, 7-12 points is moderate, and 13-21 points is at a severe level.)
Change from baseline and 70 min
The second sub-purpose Outcome:Neonates The COMFORTneo Scale
Time Frame: Change from baseline and 70 min
The scale consists of 7 items: muscle tone, alertness, facial tension, calmness / agitation, body movements, respiratory response, and crying. The lowest possible score from Newborn Comfort Behavior Scale is 6 and the highest score is 30. High scores indicate that the baby is not comfortable.
Change from baseline and 70 min
The second sub-purpose Outcome: physiological parameters of the premature infant- respiratory rate
Time Frame: Change from baseline and 70 min
Defines the change of respiratory rate (min) level.
Change from baseline and 70 min
The second sub-purpose Outcome: physiological parameters of the premature infant- heart rate (min)
Time Frame: Change from baseline and 70 min
Defines the change of heart rate (min) level.Philips IntelliVue MP40 device was used to monitor respiratory rate. Philips IntelliVue MP40 device was used to monitor heart rate (min).
Change from baseline and 70 min
The second sub-purpose Outcome: physiological parameters of the premature infant- oxygen saturation (%SpO2)
Time Frame: Change from baseline and 70 min
Defines the change of SpO2 level.
Change from baseline and 70 min
The second sub-purpose Outcome: rSO2 level
Time Frame: Change from baseline and 70 min
Defines the change of rSO2 level. The NIRS monitor (COVIDEN Operations Manual INVOS® System, Model 5100C) was used to monitor rSO2 levels. The normal range of the rSO2 measured by the device was between 55% and 85%.
Change from baseline and 70 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 20, 2020

Primary Completion (Actual)

October 20, 2021

Study Completion (Actual)

December 31, 2021

Study Registration Dates

First Submitted

January 15, 2021

First Submitted That Met QC Criteria

January 22, 2021

First Posted (Actual)

January 26, 2021

Study Record Updates

Last Update Posted (Actual)

April 18, 2023

Last Update Submitted That Met QC Criteria

April 11, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Oxygenation

Clinical Trials on Kangaroo care

Subscribe